Literature DB >> 19697439

Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies.

Marcello Deraco1, Dario Baratti, Shigeki Kusamura, Barbara Laterza, Maria Rosaria Balestra.   

Abstract

Peritoneal surface malignancies have been traditionally regarded as rapidly fatal conditions. Encouraging survival results has been associated to an innovative strategy involving aggressive cytoreductive surgery with total peritonectomy and heated intraperitoneal chemotherapy. Many controversial issues still remain regarding the optimization of the cytoreductive surgical procedures. The present article critically analyzes the relevant modifications from the original technique emerged during a 15-year experience in a single center. Operative outcome results are presented. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19697439     DOI: 10.1002/jso.21388

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

Review 1.  Cytoreductive Surgery Plus HIPEC With and Without NIPEC for Malignant Peritoneal Mesothelioma: A Propensity-Matched Analysis.

Authors:  Paul H Sugarbaker; David Chang
Journal:  Ann Surg Oncol       Date:  2021-05-03       Impact factor: 5.344

Review 2.  Cytoreductive Surgery and Peritonectomy Procedures.

Authors:  Sanket S Mehta; Aditi Bhatt; Olivier Glehen
Journal:  Indian J Surg Oncol       Date:  2016-02-03

3.  Hemodynamic Monitoring During Heated Intraoperative Intraperitoneal Chemotherapy Using the FloTrac/Vigileo System.

Authors:  Christos Mavroudis; Leonidas Alevizos; Konstantinos M Stamou; Theodosia Vogiatzaki; Savvas Eleftheriadis; Odysseas Korakianitis; Antonios A Tentes; Christos Iatrou
Journal:  Int Surg       Date:  2015-01-15

Review 4.  The Landmark Series: Appendiceal Primary Peritoneal Surface Malignancy.

Authors:  Alexandra Gangi; Rupen Shah
Journal:  Ann Surg Oncol       Date:  2021-12-01       Impact factor: 5.344

5.  Extraperitoneal Approach During Peritonectomy in the Right Upper Quadrant for Peritoneal Metastases from Ovarian Malignancies.

Authors:  Miklos Acs; Hubert Leebmann; Sebastian Häusler; Philipp Harter; Pompiliu Piso
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 6.  Update on the management of malignant peritoneal mesothelioma.

Authors:  Paul H Sugarbaker
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 7.  [Cytoreductive surgery for malignant peritoneal tumors].

Authors:  P Piso; H Leebmann; L März; M Mayr
Journal:  Chirurg       Date:  2015-01       Impact factor: 0.955

8.  Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases.

Authors:  Dario Baratti; Shigeki Kusamura; Monica Niger; Federica Perrone; Massimo Milione; Laura Cattaneo; Marcello Guaglio; Valentina Bartolini; Filippo Pietrantonio; Marcello Deraco
Journal:  Ann Surg Oncol       Date:  2020-09-24       Impact factor: 5.344

9.  Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.

Authors:  Paul H Sugarbaker
Journal:  Pleura Peritoneum       Date:  2017-05-23

10.  Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study.

Authors:  Aditi Bhatt; Pascal Rousset; Dario Baratti; Daniele Biacchi; Nazim Benzerdjeb; Ignace H J T de Hingh; Marcello Deraco; Vadim Gushchin; Praveen Kammar; Daniel Labow; Edward Levine; Brendan Moran; Faheez Mohamed; David Morris; Sanket Mehta; Aviram Nissan; Mohammad Alyami; Mohammad Adileh; Shoma Barat; Almog Ben Yacov; Kurtis Campbell; Kathleen Cummins-Perry; Delia Cortes-Guiral; Noah Cohen; Loma Parikh; Samer Alammari; Galal Bashanfer; Anwar Alshukami; Kaushal Kundalia; Gaurav Goswami; Vincent van de Vlasakker; Michelle Sittig; Paolo Sammartino; Armando Sardi; Laurent Villeneuve; Kiran Turaga; Yutaka Yonemura; Olivier Glehen
Journal:  BMJ Open       Date:  2021-07-05       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.